Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting
A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...
Clinical trial results
Gracell Biotechnologies’ GC012F Showcases Positive Data at ASCO Annual Meeting
Suzhou-based biotech firm Gracell Biotechnologies Inc., (Nasdaq: GRCL) has announced positive data for its pipeline...
AIM Vaccine’s Omicron BA.5 mRNA Vaccine Shows 73.16% Efficacy in China Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has revealed the protective efficacy of its Omicron...
HighField Biopharmaceuticals Presents Promising HF1K16 Data at ASCO Annual Meeting
Hangzhou-based biotech HighField Biopharmaceuticals has revealed the publication of an abstract at this year’s American...
Luzhu Biotechnology’s Herpes Zoster Vaccine LZ901 Concludes Phase II Study
Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading maker of human vaccines and therapeutic...
CSPC Pharmaceutical’s AlaMab Therapeutics Presents Positive ALMB-0168 Data at ASCO
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, AlaMab Therapeutics Inc.,...
Harbour Biomed’s Porustobart Combo Shows Promise in HCC Treatment, ASCO Presentation Reveals
China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib...
Abbisko Therapeutics Reports Positive Phase Ib Results for ABSK021 at ASCO
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) is poised to announce positive results from...
Shanghai Yizhong’s Paclitaxel Micelles Data to be Presented at ASCO Annual Meeting
Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091), a China-based pharmaceutical company, has announced that clinical...
Ascentage Pharma to Present Clinical Results of Four Oncology Drugs at Medical Conference
Suzhou-based Ascentage Pharma (HKG: 6855) has announced its intention to present the clinical results of...
BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at...
Sichuan Kelun Pharmaceutical to Present Clinical Data on RET Inhibitor and ADC at ASCO
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a China-based pharmaceutical company, has unveiled plans to...
Lancet Study Reveals Dalian’s Cancer Survival Rates Compared to US
A recent study published in The Lancet has conducted a comparative analysis of cancer mortality...
Asieris Pharmaceuticals to Present Phase I Results of APL-1202 Combo at ASCO
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced that it will publish the...
Oculis’ OCS-01 Achieves Primary Efficacy Endpoint in Phase III DIAMOND Trial for DME
US-based Oculis Holding AG (NASDAQ: OCS) has announced positive top-line results from Stage 1 of...
HighTide Therapeutics’ HTD1801 Meets Primary and Secondary Endpoints in Type 2 Diabetes Phase II Study
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced that its Phase II study for the...
Abbisko Therapeutics and X4 Pharmaceuticals Announce Positive Phase III Results for Mavorixafor in WHIM Syndrome
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) and its US partner X4 Pharmaceuticals Inc....
FibroGen’s Roxadustat Shows Positive Results in Phase III Chemotherapy-Induced Anemia Trial
US-based FibroGen Inc. (NASDAQ: FGEN) has announced positive topline data from a Phase III trial...
Transcenta Holdings’ TST002 Shows Positive Phase I Results for Bone Density in China
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has announced encouraging Phase I clinical study results...
Zelgen Biopharmaceuticals’ Jacktinib Studies Selected for EHA Annual Meeting
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that the results of three clinical...